25Sep 2022
Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs): A pooled analysis of type 2 diabetes trials

Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs): A pooled analysis of type 2 diabetes trials

To compare treatment effect sizes between a composite kidney outcome (CKO) and three‐point major adverse cardiovascular event (MACE‐3) outcomes with use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), and to investigate the relationship between treatment effects on CKO and MACE‐3 in patients with type 2 diabetes (T2D). A total of 12 studies fulfilled the prespecified criteria, and comprised a total of 104 987 patients with T2D. In T2D patients, treatment effect sizes were greater for kidney than for macrovascular (MACE‐3) outcomes, with important differences according to the drugs considered. CKO and MACE‐3 are independent. Caution must be taken when interpreting CKO in the absence of MACE‐3 data.

  • #endo-diabetology

Like

Save

Share